| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT04361214 Details | 2024-02-07 Interventional | 1 | 11 | Leflunomide COVID-19 | Terminated by PI - | |||
| NCT04128696 2019-002263-99 Details | 2024-02-07 Interventional | 2/3 | 315 | Pembrolizumab Carcinoma Carcinoma, Squa… Head and Neck N… Squamous Cell C… Neoplasms, Head… | The trial was stopped by the sponsor based on assessment of the clinical data Data are reported following the interim analysis decision to stop further accrual into the study and discontinue feladilimab/placebo. The study primary completion analysis results should be interpreted with consideration of the immature data | |||
| NCT04037254 Details | 2024-02-07 Interventional | 2 | - | Follicle Stimul… Hormones Niraparib Prolactin Relea… Prostatic Neopl… Prostate Adenoc… Stage IIC Prost… Stage III Prost… Stage IIIA Pros… Stage IIIB Pros… Stage IIIC Pros… Stage IVA Prost… | Protocol specified toxicity analysis - | |||
| NCT03974854 Details | 2024-02-07 Interventional | 2 | 25 | Capecitabine Gemcitabine Irinotecan Adenocarcinoma Metastatic Panc… | sponsor decision - | |||
| NCT05470491 Details | 2024-02-06 Interventional | 1/2 | - | Maraviroc Plerixafor Hematologic Neo… Neoplasms HIV Hematologic Mal… | On administrative hold for interim data analysis. - | |||
| NCT05386472 Details | 2024-02-06 Interventional | 1 | - | Nirmatrelvir Ritonavir COVID-19 | Recruitment was paused to allow time for further pharmacokinetic modelling and simulation work
to be performed to determine further dose regimens and PK blood sampling. No safety concerns
have been observed in participants enrolled to date. - | |||
| NCT04323436 2019-003097-11 Details | 2024-02-06 Interventional | 2 | 31 | Spartalizumab Carcinoma, Non-… | Study termination based on sponsor decision due to lack of tolerability observed with
capmatinib and spartalizumab combination treatment when compared to data from capmatinib single
agent studies - | |||
| NCT03722966 Details | 2024-02-06 Interventional | 2 | [1 Refs] | 34 | Nicotine Varenicline Smoking Cessati… | Following the Chantix recall, Pfizer stopped providing medication for the study and and new
study enrollments were discontinued. The study was discontinued early due to the recall of varenicline. | ||
| NCT03684694 2018-002625-38 Details | 2024-02-06 Interventional | 1/2 | 136 | Ibrutinib Loncastuximab t… Lymphoma Lymphoma, B-Cel… Lymphoma, Large… Lymphoma, Mantl… Diffuse Large B… Mantle Cell Lym… | Administrative decision - | |||
| NCT03258723 Details | 2024-02-06 Interventional | 4 | 114 | Metformin Diabetes Mellit… Diabetes | COVID-19 led to changes in study design and an early end to data collection. - | |||
| NCT00550862 Details | 2024-02-06 Interventional | 2 | 165 | Ursodeoxycholic… Fibrosis Liver Cirrhosis Liver Cirrhosis… | Study stopped by sponsor due to administrative reasons - | |||
| NCT05321251 Details | 2024-02-05 Interventional | 2/3 | [1 Refs] | 0 | Insulin Keratitis Neurotrophic Ke… | Study never commenced due to logistical issues. - | ||
| NCT04984278 2020-003271-18 Details | 2024-02-05 Interventional | 3 | 56 | Nabiximols Multiple Sclero… Muscle Spastici… Sclerosis Spasticity With… | The study was terminated based on a business decision by the Sponsor. - | |||
| NCT04596995 2019-000883-40 Details | 2024-02-05 Interventional | 3 | 43 | Rozanolixizumab Purpura, Thromb… Thrombocytopeni… Primary Immune … | Strategic Business Decision; Not a safety decision - | |||
| NCT04071236 Details | 2024-02-05 Interventional | 1/2 | - | Antibodies, Mon… Avelumab Peposertib Radium Ra 223 d… Carcinoma Neoplasms Prostatic Neopl… Castration-Resi… Metastatic Mali… Metastatic Pros… Stage IV Prosta… | End of Initial Phase of Multi-phase protocol - | |||
| NCT05351554 Details | 2024-02-02 Interventional | 2 | 1 | Antibodies, Mon… Prednisone Sarcoidosis Sarcoidosis, Ca… | Sponsor business decision not related to safety - | |||
| NCT04840615 Details | 2024-02-02 Interventional | 1 | 2 | Acetaminophen Dexamethasone Diphenhydramine Famotidine Ipilimumab LMB-100 Promethazine Mesothelioma Mesothelioma, M… | Study was closed early due to slow accrual. - | |||
| NCT04676061 Details | 2024-02-02 Interventional | 4 | 51 | Norethindrone Norethindrone A… Hemorrhage Metrorrhagia Uterine Hemorrh… Birth Control Breakthrough Bl… Contraception Implant Uterine Bleedin… | It was in the best interest of the investigator to terminate the study earlier than
anticipated. - | |||
| NCT04418167 Details | 2024-02-02 Interventional | 1 | 71 | Dabrafenib Neoplasms Solid Tumors | Sponsor decision - | |||
| NCT04380545 Details | 2024-02-02 Interventional | 1/2 | - | Fluorouracil Interferon alph… Interferon-alph… Interferons Nivolumab Carcinoma Carcinoma, Hepa… Stage III Hepat… Stage IIIA Hepa… Stage IIIB Hepa… Stage IV Hepato… Stage IVA Hepat… Stage IVB Hepat… Unresectable Fi… | PI Request - |